Diabetic retinopathy: Variations in patient therapeutic outcomes and pharmacogenomics

Pharmacogenomics and Personalized Medicine

Volumn 7, Issue , 2014, Pages 399-409

  Agarwal, Aniruddha ^a   Soliman, Mohamed K ^a   Sepah, Yasir J ^a   Do, Diana V ^a   Nguyen, Quan Dong ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Genomic markers; Genotype; Linkage; Mutation; Personalized medicine; Phenotype; Polymorphism; Responder; Therapeutic variation; VEGF mutation

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; DEXAMETHASONE; FLUOCINOLONE; HLA ANTIGEN; RANIBIZUMAB; VASCULOTROPIN;

CLINICAL TRIAL (TOPIC); DIABETIC RETINOPATHY; DNA POLYMORPHISM; ETHNIC DIFFERENCE; EXON; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC MARKER; GENETIC VARIABILITY; HUMAN; MICROANEURYSM; NONHUMAN; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PHENOTYPIC VARIATION; RETINA FLUORESCEIN ANGIOGRAPHY; RETINA FOVEA; RETINAL THICKNESS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; VISUAL ACUITY;

EID: 84919764158     PISSN: None     EISSN: 11787066     Source Type: Journal    
DOI: 10.2147/PGPM.S52821     Document Type: Review

References (105)

1. International Diabetes Federation. IDF Diabetes Atlas. 5th ed. 2011. Available from: http://www.idf.org/diabetesatlas.
2. Bourne RR, Stevens GA, White RA, et al; Vision Loss Expert Group. Causes of vision loss worldwide, 1990-2010: a systematic analysis. Lancet Glob Health. 2013;1(6):e339-e349.
3. Ahmadieh H, Shoeibi N, Entezari M, Monshizadeh R. Intravitreal bevacizumab for prevention of early postvitrectomy hemorrhage in diabetic patients: a randomized clinical trial. Ophthalmology. 2009;116(10):1943-1948.
4. Chen E, Looman M, Laouri M, et al. Burden of illness of diabetic macular edema: literature review. Curr Med Res Opin. 2010;26(7): 1587-1597.
5. Nguyen QD, Brown DM, Marcus DM, et al; RISE and RIDE Research Group. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119(4):789-801.
6. Abouammoh MA. Ranibizumab injection for diabetic macular edema: meta-analysis of systemic safety and systematic review. Can J Ophthalmol. 2013;48(4):317-323.
7. Bandello F, Casalino G, Loewenstein A, Goldstein M, Pelayes D, Battaglia Parodi M. Pharmacological approach to diabetic macular edema. Ophthalmic Res. 2014;51(2):88-95.
8. Boyer DS, Hopkins JJ, Sorof J, Ehrlich JS. Anti-vascular endothelial growth factor therapy for diabetic macular edema. Ther Adv Endocrinol Metab. 2013;4(6):151-169.
9. Patelli F, Radice P, Giacomotti E. Diabetic macular edema. Dev Ophthalmol. 2014;54:164-173.
10. Yang J, Wang X, Fuh G, et al. Comparison of binding characteristics and in vitro activities of three inhibitors of vascular endothelial growth factor A. Mol Pharm. 2014;11(10):3421-3430.
11. Stewart MW, Rosenfeld PJ. Predicted biological activity of intravitreal VEGF Trap. Br J Ophthalmol. 2008;92(5):667-668.
12. Rajendram R, Fraser-Bell S, Kaines A, et al. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Arch Ophthalmol. 2012;130(8):972-979.
13. Do DV, Schmidt-Erfurth U, Gonzalez VH, et al. The DA VINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema. Ophthalmology. 2011;118(9):1819-1826.
14. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364(20):1897-1908.
15. Korobelnik JF, Do DV, Schmidt-Erfurth U, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2014.
16. Nguyen QD, Shah SM, Khwaja AA, et al; READ-2 Study Group. Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology. 2010;117(11):2146-2151.
17. Massin P, Bandello F, Garweg JG, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care. 2010;33(11):2399-2405.
18. Mitchell P, Bandello F, Schmidt-Erfurth U, et al; RESTORE Study Group. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118(4):615-625.
19. Campochiaro PA, Brown DM, Pearson A, et al; FAME Study Group. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology. 2012;119(10):2125-2132.
20. Boyer DS, Yoon YH, Belfort R Jr, et al; Ozurdex MEAD Study Group. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014;121(10):1904-1914.
21. Lobo CL, Bernardes RC, Figueira JP, de Abreu JR, Cunha-Vaz JG. Three-year follow-up study of blood-retinal barrier and retinal thickness alterations in patients with type 2 diabetes mellitus and mild nonproliferative diabetic retinopathy. Arch Ophthalmol. 2004;122(2):211-217.
22. Nunes S, Ribeiro L, Lobo C, Cunha-Vaz J. Three different phenotypes of mild nonproliferative diabetic retinopathy with different risks for development of clinically significant macular edema. Invest Ophthalmol Vis Sci. 2013;54(7):4595-4604.
23. Cunha-Vaz J, Ribeiro L, Lobo C. Phenotypes and biomarkers of diabetic retinopathy. Prog Retin Eye Res. 2014;41:90-111.
24. Ješić M, Sajić S, Ješić M, et al. Microalbuminuria in relation to metabolic control and blood pressure in adolescents with type 1 diabetes. Archives of medical science. 2011;7(6):1037-1041.
25. Arar NH, Freedman BI, Adler SG, et al; Family Investigation of Nephropathy and Diabetes Research Group. Heritability of the severity of diabetic retinopathy: the FIND-Eye study. Invest Ophthalmol Vis Sci. 2008;49(9):3839-3845.
26. Chen JL, Luviano DM, Chen JC, Yu F, Sarraf D. Comparison of diabetic retinopathy phenotype between Latinos and Blacks. J Diabetes Complications. 2009;23(6):371-375.
27. Yohannan J, Bittencourt M, Sepah YJ, et al. Association of retinal sensitivity to integrity of photoreceptor inner/outer segment junction in patients with diabetic macular edema. Ophthalmology. 2013;120(6): 1254-1261.
28. Cunha-Vaz J. Phenotypes and biomarkers of diabetic retinopathy. Personalized medicine for diabetic retinopathy: the Weisenfeld award. Invest Ophthalmol Vis Sci. 2014;55(8):5412-5419.
29. Bai Y, Ma JX, Guo J, et al. Muller cell-derived VEGF is a significant contributor to retinal neovascularization. J Pathol. 2009;219(4): 446-454.
30. Hietala K, Forsblom C, Summanen P, Groop PH. Heritability of proliferative diabetic retinopathy. Diabetes. 2008;57(8):2176-2180.
31. Clustering of long-term complications in families with diabetes in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group. Diabetes. 1997;46(11): 1829-1839.
32. Simo-Servat O, Hernandez C, Simo R. Genetics in diabetic retinopathy: current concepts and new insights. Curr Genomics. 2013;14(5): 289-299.
33. Grassi MA, Tikhomirov A, Ramalingam S, et al. Replication analysis for severe diabetic retinopathy. Invest Ophthalmol Vis Sci. 2012;53(4): 2377-2381.
34. Huang YC, Lin JM, Lin HJ, et al. Genome-wide association study of diabetic retinopathy in a Taiwanese population. Ophthalmology. 2011;118(4):642-648.
35. Fu YP, Hallman DM, Gonzalez VH, et al. Identification of diabetic retinopathy genes through a genome-wide association study among Mexican-Americans from Starr County, Texas. J Ophthalmol. 2010; 2010:ii:861291.
36. Imperatore G, Hanson RL, Pettitt DJ, Kobes S, Bennett PH, Knowler WC. Sib-pair linkage analysis for susceptibility genes for microvascular complications among Pima Indians with type 2 diabetes. Pima Diabetes Genes Group. Diabetes. 1998;47(5):821-830.
37. Looker HC, Nelson RG, Chew E, et al. Genome-wide linkage analyses to identify Loci for diabetic retinopathy. Diabetes. 2007;56(4):1160-1166.
38. Rand LI, Krolewski AS, Aiello LM, Warram JH, Baker RS, Maki T. Multiple factors in the prediction of risk of proliferative diabetic retinopathy. N Engl J Med. 1985;313(23):1433-1438.
39. Cruickshanks KJ, Vadheim CM, Moss SE, et al. Genetic marker associations with proliferative retinopathy in persons diagnosed with diabetes before 30 yr of age. Diabetes. 1992;41(7):879-885.
40. Abhary S, Hewitt AW, Burdon KP, Craig JE. A systematic meta-analysis of genetic association studies for diabetic retinopathy. Diabetes. 2009;58(9):2137-2147.
41. Chiu C, Moss CF. The role of the external ear in vertical sound localization in the free flying bat, Eptesicus fuscus. J Acoust Soc Am. 2007;121(4):2227-2235.
42. Hudson BI, Stickland MH, Futers TS, Grant PJ. Effects of novel polymorphisms in the RAGE gene on transcriptional regulation and their association with diabetic retinopathy. Diabetes. 2001;50(6):1505-1511.
43. Tong Z, Yang Z, Patel S, et al; Genetics of Diabetes and Diabetic Complication Study Group. Promoter polymorphism of the erythropoietin gene in severe diabetic eye and kidney complications. Proc Natl Acad Sci U S A. 2008;105(19):6998-7003.
44. Cho SE, Hong KS, Shin GJ, Chung WS. The methylenetetrahydrofolate reductase C677T gene mutation is associated with hyperhomocysteinemia, cardiovascular disease and plasma B-type natriuretic peptide levels in Korea. Clinical Chemistry and Laboratory Medicine. 2006;44(9): 1070-1075.
45. Nakai K, Itoh C, Nakai K, Habano W, Gurwitz D. Correlation between C677T MTHFR gene polymorphism, plasma homocysteine levels and the incidence of CAD. Am J Cardiovasc Drugs. 2001;1(5):353-361.
46. Malaguarnera G, Gagliano C, Giordano M, et al. Homocysteine serum levels in diabetic patients with non proliferative, proliferative and without retinopathy. Biomed Res Int. 2014;2014:191497.
47. Aydemir O, Türkçüoğlu P, Güler M, et al. Plasma and vitreous homocysteine concentrations in patients with proliferative diabetic retinopathy. Retina. 2008;28(5):741-743.
48. Goldstein M, Leibovitch I, Yeffimov I, Gavendo S, Sela BA, Loewenstein A. Hyperhomocysteinemia in patients with diabetes mellitus with and without diabetic retinopathy. Eye. 2004;18(5):460-465.
49. Liang S, Pan M, Hu N, et al. Association of angiotensin-converting enzyme gene 2350 G/A polymorphism with diabetic retinopathy in Chinese Han population. Mol Biol Rep. 2013;40(1):463-468.
50. Manea SA, Robciuc A, Guja C, Heltianu C. Identification of gene variants in NOS3, ET-1 and RAS that confer risk and protection against microangiopathy in type 2 diabetic obese subjects. Biochem Biophys Res Commun. 2011;407(3):486-490.
51. dos Santos KG, Canani LH, Gross JL, Tschiedel B, Souto KE, Roisenberg I. The -106CC genotype of the aldose reductase gene is associated with an increased risk of proliferative diabetic retinopathy in Caucasian-Brazilians with type 2 diabetes. Mol Genet Metab. 2006;88(3):280-284.
52. Wang J, Yang MM, Li YB, Liu GD, Teng Y, Liu XM. Association of CFH and CFB gene polymorphisms with retinopathy in type 2 diabetic patients. Mediators Inflamm. 2013;2013:748435.
53. Chen M, Lin WR, Lu CH, et al. Chimerin 2 genetic polymorphisms are associated with non-proliferative diabetic retinopathy in Taiwanese type 2 diabetic patients. J Diabetes Complications. 2014;28(4):460-463.
54. Arndt C, Leclercq I, Nazeyrollas P, et al. Association of endothelial lipase Thr111Ile polymorphism with proliferative retinopathy in type 2 diabetes patients. Diabetes and Metabolism. 2014.
55. Taverna MJ, Sola A, Guyot-Argenton C, et al. eNOS4 polymorphism of the endothelial nitric oxide synthase predicts risk for severe diabetic retinopathy. Diabet Med. 2002;19(3):240-245.
56. Abhary S, Burdon KP, Casson RJ, Goggin M, Petrovsky NP, Craig JE. Association between erythropoietin gene polymorphisms and diabetic retinopathy. Arch Ophthalmol. 2010;128(1):102-106.
57. Gong JY, Deng DT, Sun YH. Association of platelet glycoprotein receptor alpha2beta1 integrin and glycoprotein IIIa gene polymorphisms with diabetic retinopathy: evidence from 3007 subjects. Curr Eye Res. 2014;30:1-8.
58. Katakami N, Matsuhisa M, Kaneto H, et al. Monocyte chemoattractant protein-1 (MCP-1) gene polymorphism as a potential risk factor for diabetic retinopathy in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract. 2010;89(1):e9-e12.
59. Yigit S, Karakus N, Inanir A. Association of MTHFR gene C677T mutation with diabetic peripheral neuropathy and diabetic retinopathy. Mol Vis. 2013;19:1626-1630.
60. Mankoc Ramus S, Kumse T, Globocnik Petrovic M, Petrovic D, Cilensek I. SNP rs2073618 of the osteoprotegerin gene is associated with diabetic retinopathy in Slovenian patients with type 2 diabetes. Biomed Res Int. 2013;2013:364073.
61. Ng ZX, Kuppusamy UR, Iqbal T, Chua KH. Receptor for advanced glycation end-product (RAGE) gene polymorphism 2245G/A is associated with pro-inflammatory, oxidative-glycation markers and sRAGE in diabetic retinopathy. Gene. 2013;521(2):227-233.
62. Zhang HM, Chen LL, Wang L, et al. Association of 1704G/T and G82S polymorphisms in the receptor for advanced glycation end products gene with diabetic retinopathy in Chinese population. J Endocrinol Invest. 2009;32(3):258-262.
63. Sobrin L, Green T, Sim X, et al; Family Investigation of Nephropathy and Diabetes-Eye Research Group, Wellcome Trust Case Control Consortium 2. Candidate gene association study for diabetic retinopathy in persons with type 2 diabetes: the Candidate gene Association Resource (CARe). Invest Ophthalmol Vis Sci. 2011;52(10):7593-7602.
64. Luo J, Zhao L, Chen AY, et al. TCF7L2 variation and proliferative diabetic retinopathy. Diabetes. 2013;62(7):2613-2617.
65. Brondani LA, de Souza BM, Duarte GC, et al. The UCP1 -3826A/G polymorphism is associated with diabetic retinopathy and increased UCP1 and MnSOD2 gene expression in human retina. Invest Ophthalmol Vis Sci. 2012;53(12):7449-7457.
66. Crispim D, Fagundes NJ, dos Santos KG, et al. Polymorphisms of the UCP2 gene are associated with proliferative diabetic retinopathy in patients with diabetes mellitus. Clin Endocrinol. 2010;72(5): 612-619.
67. Han L, Zhang L, Xing W, et al. The associations between VEGF gene polymorphisms and diabetic retinopathy susceptibility: a meta-analysis of 11 case-control studies. J Diabetes Res. 2014;2014:805801.
68. Ishida S, Usui T, Yamashiro K, et al. VEGF164 is proinflammatory in the diabetic retina. Invest Ophthalmol Vis Sci. 2003;44(5):2155-2162.
69. Funatsu H, Yamashita H, Sakata K, et al. Vitreous levels of vascular endothelial growth factor and intercellular adhesion molecule 1 are related to diabetic macular edema. Ophthalmology. 2005;112(5):806-816.
70. Petrovic MG, Korosec P, Kosnik M, et al. Local and genetic determinants of vascular endothelial growth factor expression in advanced proliferative diabetic retinopathy. Mol Vis. 2008;14:1382-1387.
71. Vincenti V, Cassano C, Rocchi M, Persico G. Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3. Circulation. 1996;93(8):1493-1495.
72. Brogan IJ, Khan N, Isaac K, Hutchinson JA, Pravica V, Hutchinson IV. Novel polymorphisms in the promoter and 5' UTR regions of the human vascular endothelial growth factor gene. Hum Immunol. 1999;60(12): 1245-1249.
73. Stevens A, Soden J, Brenchley PE, Ralph S, Ray DW. Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res. 2003;63(4):812-816.
74. Watson CJ, Webb NJ, Bottomley MJ, Brenchley PE. Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine. 2000;12(8):1232-1235.
75. Awata T, Kurihara S, Takata N, et al. Functional VEGF C-634G polymorphism is associated with development of diabetic macular edema and correlated with macular retinal thickness in type 2 diabetes. Biochem Biophys Res Commun. 2005;333(3):679-685.
76. El-Shazly SF, El-Bradey MH, Tameesh MK. Vascular endothelial growth factor gene polymorphism prevalence in patients with diabetic macular oedema and its correlation with anti-vascular endothelial growth factor treatment outcomes. Clin Experiment Ophthalmol. 2014;42(4):369-378.
77. Huez I, Bornes S, Bresson D, Creancier L, Prats H. New vascular endothelial growth factor isoform generated by internal ribosome entry site-driven CUG translation initiation. Mol Endocrinol. 2001;15(12): 2197-2210.
78. Feghhi M, Nikzamir A, Esteghamati A, Mahmoudi T, Yekaninejad MS. Relationship of vascular endothelial growth factor (VEGF) +405 G/C polymorphism and proliferative retinopathy in patients with type 2 diabetes. Transl Res. 2011;158(2):85-91.
79. Bleda S, De Haro J, Varela C, Esparza L, Ferruelo A, Acin F. Vascular endothelial growth factor polymorphisms are involved in the late vascular complications in Type II diabetic patients. Diab Vasc Dis Res. 2012;9(1):68-74.
80. Wang H, Cheng JW, Zhu LS, et al. Meta-analysis of association between the -2578C/A polymorphism of the vascular endothelial growth factor and retinopathy in type 2 diabetes in Asians and Caucasians. Ophthalmic Res. 2014;52(1):1-8.
81. Gong JY, Sun YH. Association of VEGF gene polymorphisms with diabetic retinopathy: a meta-analysis. PLoS One. 2013; 8(12):e84069.
82. Carter JG, Cherry J, Williams K, Turner S, Bates DO, Churchill AJ. Splicing factor polymorphisms, the control of VEGF isoforms and association with angiogenic eye disease. Curr Eye Res. 2011;36(4): 328-335.
83. Veloso CE, de Almeida LN, Recchia FM, Pelayes D, Nehemy MB. VEGF gene polymorphism and response to intravitreal ranibizumab in neovascular age-related macular degeneration. Ophthalmic Res. 2014;51(1):1-8.
84. Lotery AJ, Gibson J, Cree AJ, et al; Alternative Treatments to Inhibit VEGF in Patients with Age-Related Choroidal Neovascularisation (IVAN) Study Group. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age-related macular degeneration in the IVAN Study. Ophthalmology. 2013;120(12):2637-2643.
85. Abedi F, Wickremasinghe S, Richardson AJ, et al. Variants in the VEGFA gene and treatment outcome after anti-VEGF treatment for neovascular age-related macular degeneration. Ophthalmology. 2013;120(1):115-121.
86. Hagstrom SA, Ying GS, Pauer GJ, et al; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group. VEGFA and VEGFR2 gene polymorphisms and response to anti-vascular endothelial growth factor therapy: comparison of age-related macular degeneration treatments trials (CATT). JAMA Ophthalmol. 2014;132(5):521-527.
87. Dabir SS, Das D, Nallathambi J, Mangalesh S, Yadav NK, Schouten JS. Differential systemic gene expression profile in patients with diabetic macular edema: responders versus nonresponders to standard treatment. Indian J Ophthalmol. 2014;62(1):66-73.
88. El-Bab MF, Zaki NS, Mojaddidi MA, Al-Barry M, El-Beshbishy HA. Diabetic retinopathy is associated with oxidative stress and mitigation of gene expression of antioxidant enzymes. Int J Gen Med. 2013;6: 799-806.
89. Mastropasqua R, Toto L, Cipollone F, Santovito D, Carpineto P, Mastropasqua L. Role of microRNAs in the modulation of diabetic retinopathy. Prog Retin Eye Res. 2014;43C:92-107.
90. Kato M, Castro NE, Natarajan R. MicroRNAs: potential mediators and biomarkers of diabetic complications. Free Radic Biol Med. 2013;64: 85-94.
91. Jain RK, Duda DG, Willett CG, et al. Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol. 2009;6(6): 327-338.
92. Snyderman R, Williams RS. Prospective medicine: the next health care transformation. Acad Med. 2003;78(11):1079-1084.
93. Chawla NV, Davis DA. Bringing big data to personalized healthcare: a patient-centered framework. J Gen Intern Med. 2013;28(Suppl 3): S660-S665.
94. Chen JJ, Lin WJ, Chen HC. Pharmacogenomic biomarkers for personalized medicine. Pharmacogenomics. 2013;14(8):969-980.
95. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364-1379.
96. Niu W, Qi Y, Wu Z, Liu Y, Zhu D, Jin W. A meta-analysis of receptor for advanced glycation end products gene: four well-evaluated polymorphisms with diabetes mellitus. Mol Cell Endocrinol. 2012;358(1): 9-17.
97. Niu W, Qi Y. An updated meta-analysis of methylenetetrahydrofolate reductase gene 677C/T polymorphism with diabetic nephropathy and diabetic retinopathy. Diabetes Res Clin Pract. 2012;95(1):110-118.
98. Maeda M, Yamamoto I, Fukuda M, et al. MTHFR gene polymorphism is susceptible to diabetic retinopathy but not to diabetic nephropathy in Japanese type 2 diabetic patients. J Diabetes Complications. 2008;22(2):119-125.
99. Maeda M, Yamamoto I, Fukuda M, et al. MTHFR gene polymorphism as a risk factor for diabetic retinopathy in type 2 diabetic patients without serum creatinine elevation. Diabetes Care. 2003;26(2):547-548.
100. Glauber HS, Rishe N, Karnieli E. Introduction to personalized medicine in diabetes mellitus. Rambam Maimonides Med J. 2014;5(1):e0002.
101. Aerpio Therapeutics. The TIME-2 Study: A Phase 2 Study of AKB-9778, A Novel Tie-2 Activator, in Patients with Diabetic Macular Edema; 2014. Available from: https://clinicaltrials.gov/ct2/show/NCT02050828.
102. River Vision Development Corporation. A Phase 1, Open-Label Study of Teprotumumab in Patients with Diabetic Macular Edema (DME). 2014.
103. Guzman-Aranguez A, Loma P, Pintor J. Small-interfering RNAs (siRNAs) as a promising tool for ocular therapy. Br J Pharmacol. 2013;170(4):730-747.
104. Vacca O, Darche M, Schaffer DV, et al. AAV-mediated gene delivery in Dp71-null mouse model with compromised barriers. Glia. 2014;62(3):468-476.
105. Adhi M, Cashman SM, Kumar-Singh R. Adeno-associated virus mediated delivery of a non-membrane targeted human soluble CD59 attenuates some aspects of diabetic retinopathy in mice. PLoS One. 2013;8(10):e79661.